CN112225703A - Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity - Google Patents
Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity Download PDFInfo
- Publication number
- CN112225703A CN112225703A CN202011046968.XA CN202011046968A CN112225703A CN 112225703 A CN112225703 A CN 112225703A CN 202011046968 A CN202011046968 A CN 202011046968A CN 112225703 A CN112225703 A CN 112225703A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- substituted
- substituent
- heteroatom
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 34
- 201000010099 disease Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 title claims abstract description 17
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 17
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 12
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title claims abstract 10
- 229940079593 drug Drugs 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 239000000126 substance Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 16
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 7
- 206010012289 Dementia Diseases 0.000 claims abstract description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 7
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 7
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 7
- 239000000651 prodrug Substances 0.000 claims abstract description 7
- 229940002612 prodrug Drugs 0.000 claims abstract description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract description 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 208000012661 Dyskinesia Diseases 0.000 claims abstract description 6
- 206010024229 Leprosy Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 5
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 5
- 230000003287 optical effect Effects 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- -1 5-methyl-1H-pyrazol-3-yl Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 229940124786 LRRK2 inhibitor Drugs 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 5
- 125000001769 aryl amino group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 5
- 229910017711 NHRa Inorganic materials 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 3
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 claims description 3
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052705 radium Inorganic materials 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000006993 memory improvement Effects 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 3
- 208000032839 leukemia Diseases 0.000 abstract description 3
- 208000003154 papilloma Diseases 0.000 abstract description 3
- 108060006633 protein kinase Proteins 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102220577899 Leucine-rich repeat serine/threonine-protein kinase 2_G2019S_mutation Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000004332 Evans syndrome Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101100021877 Homo sapiens LRRK2 gene Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 101150081013 LRRK2 gene Proteins 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000019748 bullous skin disease Diseases 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
- 229960003337 entacapone Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- CVLXNRIQVFIVGY-UHFFFAOYSA-N 2-[[1-[2-fluoro-4-[[5-methyl-4-(1-propan-2-ylpyrazol-4-yl)pyrimidin-2-yl]amino]phenyl]piperidin-4-yl]-methylamino]ethanol Chemical compound CC(C)n1cc(cn1)-c1nc(Nc2ccc(N3CCC(CC3)N(C)CCO)c(F)c2)ncc1C CVLXNRIQVFIVGY-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- YEVOZZZLKJKCCD-UHFFFAOYSA-N HG-10-102-01 Chemical compound C1=C(Cl)C(NC)=NC(NC=2C(=CC(=CC=2)C(=O)N2CCOCC2)OC)=N1 YEVOZZZLKJKCCD-UHFFFAOYSA-N 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229940127397 Poly(ADP-Ribose) Polymerase Inhibitors Drugs 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- WPOXAFXHRJYEIC-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CN=2)=C1 WPOXAFXHRJYEIC-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000036959 susceptibility to 3 leprosy Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity, and belongs to the field of medicines. The medicine comprises at least one of a compound shown in chemical formula 1, an optical isomer thereof, a prodrug thereof, a salt thereof, a hydrate thereof, a solvate thereof, an N-oxide thereof and a deuterated analog thereof, has a good inhibiting effect on LRRK2 kinase or abnormal LRRK2 mutant kinase, and can be used for treating or preventing diseases related to the activity of LRRK2 kinase or abnormal LRRK2 mutant kinase, such as Alzheimer's disease, L-dopa induced dyskinesia, Parkinson's disease, dementia, kidney cancer, breast cancer, prostate cancer, leukemia, papilloma, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity.
Background
The protein encoded by the LRRK2 gene includes a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, an MLK-domain, and a WD40 domain. There is a lot of genetic and biochemical evidence that LRRK2 kinase activity is associated with susceptibility to parkinson's Disease PD, pathogenic mutations in the LRRK2 gene (especially the most common Gly2019Ser mutation) increase LRRK2 kinase activity and decrease the rate of GTP hydrolysis in cells and tissues, and that blocking these activities by small molecule LRRK2 kinase inhibitors may also provide neuroprotection in certain PD models, which discovery has made LRRK2 the most promising target for treating Parkinson's Disease (PD) (Tolosa et al, Nature Reviews in Neurology, vol.16, 2020, pp.97-10; Paisan-Ruiz et al, j.kinson's Disease, vol.3, 2013, pp.85-103; Guo et al, Experimental Research, vol.313(16), 2007, 3658-3670; Andrew b.west, Experimental, pp.298, 2017.245, pp.236). LRRK2 was identified as a gene potentially associated with increased susceptibility to Crohn's disease and susceptibility to leprosy (Zhang et al, New England J.Med., Vol.361, 2009, pp.2609-2618; Barrett et al, Nature Genetics, Vol.40, 2008, pp.955-962); it is also associated with spinal rigidity (ankyissing spondifications) (Danoy et al, PLoS Genetics, Vol 6(12), 2010, pp.1-5) and Amyotrophic lateral Sclerosis (Shtilans et al, Amyotrophic lateral Sclerosis, 2011, pp.1-7).
LRRK2 is also associated with Alzheimer's disease conversion from mild cognitive impairment (WO 2007149798); l-dopa-induced dyskinesia (Hurley et al, Eur. J, Neurosci, Vol.26, 2007, pp.171-177); CNS disorders associated with proliferation and migration of neuroblasts, and modulation of LRRK2 can be used to improve neurological outcome after ischemic injury and stimulate CNS functional recovery after neuronal injury, such as ischemic stroke, traumatic brain injury, or spinal cord injury (Milosevic et al, neuroregen, vol.4, 2009, 25; Zhang et al, j.neurosci.res, vol.88, 2010, pp.3275-3281). Other diseases: including diabetes, obesity, motor neuron disease, epilepsy, and some cancers (Rubinsztein et al, nat. rev. drug Discovery, vol.11, 2012, 709-. Cancers such as renal, breast, prostate (e.g. solid tumors), blood and lung cancers and Acute Myeloid Leukemia (AML) (WO 2011038572); lymphomas and leukemias (Ray et al, j.immunolo., vol.230, 2011, 109); papillary renal and thyroid carcinomas (Bredan D Looyenga et al, Proc Natl Acad Sci U S A, Vol.108(4), 2011, pp.1439-44); multiple myeloma (Chapman et al, Nature, Vol.471, 2011, pp.467-472). Diseases of the immune system: including rheumatoid arthritis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure erythrodysgenesis, Idiopathic Thrombocytopenic Purpura (ITP), Evans syndrome, vasculitis, bullous skin Disease, type I diabetes, Huggen's syndrome (Sjogren's syndrome), Devickers ' Disease, and inflammatory diseases (Nakamura et al, DNA Res., Vol.13(4), 2006, pp.169-183; Engel et al, Pharmacol. Rev., Vol.63, 2011, 127. minus 156; Homam et al, J.Clin. Neurocusu Disease, Vol.12, 2010, 91-102.) pulmonary diseases such as chronic obstructive pulmonary Disease and idiopathic pulmonary fibrosis (Araya et al, Intern.52, Internally. 2013, as inhibitors of bacterial infection by bacteria such as LR kinase, intracellular kinase (RK et al, RK. 19. 2, RK 3, and RK kinase) for increasing the host cell infection, nat.rev., 2012, 709-; araya et al, lntern.med., vol.52, 2013, 95-2303; gutierrez, Biochemical Society Conference, Leucine rich repeat kinase 2. ten year eyes from the road to the therapeutic intervention, Henley Business School, UK 12July 2016), HIV, West Nile virus, and Cherokee virus (Shoji-Kawata et al, Nature, Vol.494, 2013, pp.201-206). Also for other a-synucleinopathies (Orenstein et al, Nature Neurosci., Vol.16, 2013, 394-406), Tau proteinopathies (Li et al, neuroodegen.Dis., Vol.7, 2010, pp.265-271), Alzheimer's disease and other neurodegenerative diseases (Nixon, Nat.Med., Vol.19, 2013, pp.983-97) and gaucher's disease (Westbrook et al, trends.mol.Med., Vol.17, 2011, 485-493); tauopathies characterized by hyperphosphorylation of Tau, such as granule disease of argentism, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, and hereditary frontotemporal dementia and parkinson's disease associated with chromosome 17 (Jakes R et al, biochemica Acta, vol.1739,2005, pp. 240-250); microglial proinflammatory responses (Moehle et al, J.Neuroscience, Vol.32, 2012, pp.1602-1611).
Thus, compounds that effectively modulate LRRK2 activity may provide treatment for diseases or conditions mediated by LRRK2 that are neurodegenerative diseases, cancer, inflammatory diseases, bacterial, viral infections, and other diseases.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a medicament for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity.
To achieve the above objects, the present invention provides a medicament for treating or preventing diseases associated with LRRK2 kinase or abnormal LRRK2 mutant kinase activity, comprising an LRRK2 inhibitor, wherein the LRRK2 inhibitor comprises at least one of a compound represented by chemical formula 1, an optical isomer thereof, a prodrug thereof, a salt thereof, a hydrate thereof, a solvate thereof, an N-oxide thereof, and a deuterated analog thereof;
[ chemical formula 1]
In chemical formula 1, L1、L2、L3Are each independently C or N; l is4C, N, O or S;
R1independently is an unsubstituted or an amide group,
R2independently is unsubstituted, -H, -NHAr, -CH ═ CHPh,Or a 5-to 8-membered cyclic heterocyclic group containing at least one heteroatom at N, O, which is unsubstituted or substituted with a first substituent,
R3is unsubstituted, -H, halogen, C1-10Hydrocarbyl, or-NHRa;
R4independently-H, -NHAr, -CH ═ CHPh, -NHRaA substituted or unsubstituted 5-to 8-membered heterocyclylvinyl group containing N, O, S at least one heteroatom, C1-5Straight-chain or branched alkylaminosulfonyl C6-10Arylamino, di (C)1-5Straight-chain or branched alkyl) phosphoric acid group C6-10An arylamino group,A 5-to 8-membered ring heterocyclyl group containing at least one heteroatom at N, O, or a 5-to 8-membered ring heterocyclylamino group, unsubstituted or substituted with a second substituent,
Wherein L is5is-O-, -S-, or-NH-,
Y1is C unsubstituted or substituted by a third substituent1-10A linear or branched alkyl group,
ring Y is a benzene ring, or a 4-to 8-membered cycloheterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a fourth substituent;
R6is unsubstituted or-H;
R7is-H, C1-10Hydrocarbyl, - (CH)2)nOH、-ORc、-O(CH2)nRaHalogen, or a 4 to 8 membered ring heterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a third substituent;
R8、R9、R10、R11are all independently-H, C1-10Hydrocarbyl, - (CH)2)nOH、-O(CH2)nRa、-C(O)ORaHalogen, -CF3or-OCF3;
Each RaAre all independently-H, C1-10Hydrocarbyl radical, C1-10Cycloalkyl, aryl, or unsubstituted or substituted with a fifth substituent, 5-to 8-membered cycloheterocycloalkyl or heterocycloaryl containing at least one heteroatom of N, O;
each RbAre all independently-H, C1-10Hydrocarbyl, -O (CH)2)nRa、-NRaRcOr a 3-to 8-membered ring heterocyclic group containing at least one heteroatom at N, O, unsubstituted or substituted with a sixth substituent;
each RcAre all independently-H, C1-10Hydrocarbyl, - (CH)2)nOH, aryl, or a 4 to 8 membered ring heterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a third substituent;
each RdAre all independently-H or-O (CH)2)nRa;
The first substituent, the second substituent, the fourth substituent, the fifth substituent and the sixth substituent are respectively and independently-OH, halogen, -CN, nitro-NH2、C1-10Hydrocarbyl, substituted or unsubstituted C3-10Cycloalkyl, substituted or unsubstituted N-containing,At least one of 3 to 8 membered ring heterocycloalkyl of at least one heteroatom in O;
each n is independently selected from any integer from 0 to 4.
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
the R is3Is halogen or C1-10A hydrocarbyl group; the R is4Is C1-5Straight-chain or branched alkylaminosulfonyl C6-10Arylamino, di (C)1-5Straight-chain or branched alkyl) phosphoric acid group C6-10An arylamino group,Or a 5-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a second substituent; the R is7Is composed ofRbIs C1-10Hydrocarbyl radicals, -NRaRcOr by C1-10A 3-to 8-membered, hydrocarbyl-substituted heterocyclic group containing at least one heteroatom from N, O, RaIs C1-10Hydrocarbyl radical, RcIs- (CH)2)nOH; the R is10、R11Are all independently-H, -O (CH2)nRa、C1-10Hydrocarbyl or halogen.
Further preferably, said R3is-F, -Cl or-CH3(ii) a The R is4Is composed of The R is7Is composed of The R is10、R11Are all independently-H, -OCH3、-CH3or-F.
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
said L4N, S or O; the R is5Is composed ofOr by-O (CH)2)nRaAt least one substituted phenyl group of halogen; rbis-O (CH)2)nRa;Rais-H, or a 5 to 8 membered cyclic heterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a fifth substituent; rdis-H or-O (CH)2)nRa。
Further preferably, said L4N, S or O; the R is5Is composed of The R isbIs composed ofRdis-H or-OCH3。
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
the R is4Is a quilt C1-10A 5 to 8 membered ring heterocyclylamino substituted with a hydrocarbon group; said L4N, S or O; the R is7Is O (CH)2)nRa,RaIs aryl or a 5 to 8 membered ring heterocycloalkyl or heterocycloaryl containing at least one heteroatom of N, O, unsubstituted or substituted with a fifth substituent.
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
the R is2Is a 5-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a first substituent; said L4Is N; the R is4is-CH ═ CHPh, or a substituted or unsubstituted 4 to 8 membered ring heterocyclylvinyl group containing at least one heteroatom from N, O, S; the R is5Is composed of
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
the R is1Is an amide group; the R is3Is C1-10A hydrocarbyl group; the R is4Is a 5 to 8 membered ring heterocyclylamino group; the R is7Is composed ofThe R isbIs a 3-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a sixth substituent; the R is9is-O (CH)2)nRa。
Preferably, the structural formula of the compound represented by chemical formula 1 is as follows:
preferably, the compound represented by chemical formula 1 is any one of the following compounds:
(1) (1S, 2S, 3R, 4R) -3- [ [ 5-fluoro-2- [ 3-methyl-4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] bicyclo [2.2.1] hept-5-ene-2-carboxamide;
(2) n-tert-butyl-3- [ [ 5-methyl-2- [4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] benzenesulfonamide;
(3)2- [ [1- [ 2-fluoro-4- [ [ 5-methyl-4- (1-prop-2-ylpyrazol-4-yl) pyrimidin-2-yl ] amino ] phenyl ] piperidin-4-yl ] -methylamino ] ethanol;
(4) 5-chloro-4-N- (2-dimethylphosphorylphenyl) -2-N- [ 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl ] pyrimidine-2, 4-diamine;
(5)1- (4-methylphenyl) -3- [5- [7- (3-morpholin-4-ylpropoxy) quinazolin-4-yl ] sulfonyl-1, 3, 4-thiadiazol-2-yl ] urea;
(6) n- (2-chloro-5-methoxyphenyl) -6-methoxy-7- [ (1-methylpiperidin-4-yl) methoxy ] quinazolin-4-amine;
(7) 8-bromo-2- [ (1-methylpiperidin-4-yl) amino ] -4- (4-phenoxyaniline) -6H-pyridin [4,3-d ] pyrimidin-5-one;
(8)6- (4-methylpiperazin-1-yl) -N- (5-methyl-1H-pyrazol-3-yl) -2- [ ((E) -2-phenylethenyl ] pyrimidin-4-amine;
(9) 6-ethyl-3- [ 3-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] anilino ] -5- (oxa-4-ylamino) pyrazine-2-carboxamide;
(10) (16E) -11- (2-pyrrolidin-1-ethoxy) -14, 19-dioxin-5, 7, 27-triazacyclo [19.3.1.12,6.18,12] hepta-1 (24), 2(27), 3,5,8(26), 9,11,16,21(25), 22-decene.
Preferably, the disease includes at least one of neurodegenerative diseases, pre-cancerous conditions and cancers, autoimmune diseases, inflammation.
Preferably, the disease comprises at least one of alzheimer's disease, L-dopa induced dyskinesia, parkinson's disease, enhanced cognitive memory, central nervous system disorders, dementia, amyotrophic lateral sclerosis, kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
It is to be noted that the above hydrocarbon groups each include an alkyl group as well as an unsaturated hydrocarbon group such as an alkenyl group; the above halogens include F, Cl, Br, etc.; ar represents an aryl group such as phenyl, naphthyl, etc.; ph represents a phenyl group; the 5-to 8-membered heterocyclic group containing at least one heteroatom of N, O which is unsubstituted or substituted by a first substituent means that the atoms constituting the 5-to 8-membered ring contain at least one heteroatom of N, O in addition to carbon atoms, and the 5-to 8-membered ring is unsubstituted or substituted by the first substituent, and the other meanings are as similarly expressed; two (C)1-5Straight-chain or branched alkyl) phosphoric acid group C6-10In the arylamino group, the substituent alkyl groups on the phosphate group may be the same or different, e.g.Etc.; quilt C1-10The 5-to 8-membered ring heterocyclylamino substituted with a hydrocarbon group means that a 5-to 8-membered ring heterocyclyl group in the 5-to 8-membered ring heterocyclylamino is substituted with C1-10Hydrocarbyl substitution; r2Independently is unsubstituted, -H, -NHAr, -CH ═ CHPh,Or a 5-to 8-membered ring heterocyclic group containing at least one heteroatom at N, O, unsubstituted or substituted with a first substituent, refers to R2Independently is unsubstituted, -H, -NHAr, -CH ═ CHPh,A 5-to 8-membered ring heterocyclic group containing N, O at least one hetero atom without substituent, or a 5-to 8-membered ring heterocyclic group containing N, O at least one hetero atom substituted with a first substituent, and the like.
Compared with the prior art, the invention has the beneficial effects that: the medicaments of the invention comprise specific inhibitors of LRRK2, are effective in the treatment or prevention of diseases associated with the activity of LRRK2 kinase or any mutant thereof (e.g. LRRK2 mutant G2019S), e.g. are useful in the prevention and treatment of neurodegenerative diseases such as parkinson's disease and other lewy body type diseases, including diffuse lewy body disease, the lewy body variant of alzheimer's disease, combined parkinson's disease and alzheimer's disease, multiple system atrophy and dementia with lewy bodies, etc.; can also be used for preventing and treating cancer such as renal cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myelogenous leukemia, multiple myeloma, melanoma, etc.; it can also be used for preventing and treating autoimmune diseases and inflammations, such as leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
Drawings
FIG. 1 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2G2019S determined by experimental example 11 for the compound of example 1;
FIG. 2 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2G2019S determined by experimental example 11 for the compound of example 2;
FIG. 3 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2G2019S determined by experimental example 11 for the compound of example 4;
FIG. 4 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2G2019S determined by experimental example 11 for the compound of example 7;
FIG. 5 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2G2019S determined by experimental example 11 for the compound of example 9.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
The present invention relates to a drug for treating or preventing diseases associated with LRRK2 kinase or abnormal LRRK2 mutant kinase activity, comprising LRRK2 inhibitor, wherein the LRRK2 inhibitor comprises at least one of compound represented by chemical formula 1, optical isomer thereof, prodrug thereof, pharmaceutically acceptable salt thereof, hydrate thereof, solvate thereof, N-oxide thereof, deuterated analog thereof.
According to the present invention, the compound represented by chemical formula 1 can be used for preventing and treating related disorders caused by mutation of LRRK2 or abnormal LRRK2, such as alzheimer's disease, L-dopa induced dyskinesia, parkinson's disease, dementia, amyotrophic lateral sclerosis, kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, ankylosing spondylitis, and the like.
According to the present invention, the compound represented by chemical formula 1 may be used for preventing and treating diseases or conditions mediated at least in part by LRRK2 or abnormal LRRK2 mutation, which are neurodegenerative diseases, for example, Central Nervous System (CNS) disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), dementia including lewy body dementia and vascular dementia, Amyotrophic Lateral Sclerosis (ALS), age-related memory dysfunction, mild cognitive impairment (e.g., including transition from mild cognitive impairment to alzheimer's disease), silvery particle disease, lyhehal disease (e.g., niemann-pick C, gaucher's disease), corticobasal degeneration, progressive supranuclear palsy, hereditary frontopal dementia and parkinson's disease associated with chromosome 17 (FTDP-17), withdrawal symptoms/relapse associated with drug addiction, L-dopa-induced dyskinesia, Huntington's Disease (HD), and HIV-associated dementia (HAD). Disorders are ischemic diseases of organs including, but not limited to, the brain, heart, kidney, and liver.
In some embodiments, the compound of formula 1 is used for treating a disease or condition mediated at least in part by LRRK2 or an aberrant LRRK2 mutation is cancer, such as thyroid cancer, renal cancer (including papillary renal cancer), breast cancer, lung cancer, blood cancer, and prostate cancer (e.g., solid tumors), leukemia (including Acute Myeloid Leukemia (AML), or lymphoma.
In other embodiments, the compound of formula 1 is used to treat a disease or condition mediated at least in part by LRRK2 or an aberrant LRRK2 mutation is an inflammatory disorder. The inflammatory disorder is an inflammatory bowel disease, such as crohn's disease or ulcerative colitis (the two together generally being referred to as inflammatory bowel disease). The inflammatory disease is leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
In other embodiments, the compounds of formula 1 are useful for treating other diseases mediated at least in part by LRRK2 or aberrant LRRK2 mutations: multiple sclerosis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure red cell aplasia, Idiopathic Thrombocytopenic Purpura (ITP), Evan's syndrome, vasculitis, bullous skin disease, type 1 diabetes, Hugger's syndrome, Devkker's disease, and inflammatory myopathy.
According to the present invention, the compound represented by chemical formula 1 may be used in the form of a pharmaceutically acceptable salt thereof. Here, the pharmaceutically acceptable salt may be an acid addition salt formed from a pharmaceutically acceptable free acid. Acid addition salts can be obtained from inorganic acids (e.g., hydrochloric, nitric, phosphoric, sulfuric, bromic, hydroiodic, nitrous, phosphorous, and the like), nontoxic organic acids (e.g., aliphatic mono-and di-carboxylic acid esters, phenyl-substituted alkanoates, hydroxyalkanoates and alkanoates, aromatic acids, aliphatic and aromatic sulfonic acids, and the like), or organic acids (e.g., acetic, benzoic, citric, lactic, maleic, gluconic, methanesulfonic, 4-toluenesulfonic, tartaric, fumaric, and the like). The acid addition salts may be obtained from pharmaceutically non-toxic salts including sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate (decanoate), octanoate, acrylate, formate, isobutyrate, decanoate (caprate), heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1, 4-dioleate, hexane-1, 6-oleate, benzoate, chlorobenzoate, methyl benzoate, dinitrobenzoate, hydroxykorate, tolylbenzoate phthalate, terephthalate, benzenesulfonate, tosylate, Chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, beta-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, bane-2-sulfonate, mandelate and the like.
According to the present invention, the acid addition salt may be prepared by a conventional method, for example, by dissolving the compound represented by chemical formula 1 or a derivative thereof in an organic solvent such as methanol, ethanol, acetone, dichloromethane or acetonitrile, and adding an organic acid or an inorganic acid thereto to obtain a precipitate, and then filtering and drying the precipitate, or subjecting the solvent and an excess of the acid to vacuum distillation, drying and then crystallizing in the presence of the organic solvent.
In addition, according to the present invention, the compound represented by chemical formula 1 may be prepared and used in the form of a pharmaceutically acceptable metal salt thereof. Specifically, the alkali metal or alkaline earth metal salt can be obtained by the following method: for example, the compound is dissolved in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, the undissolved compound salt is filtered off, and the filtrate is evaporated to dryness. Here, sodium, potassium or calcium salts are pharmaceutically suitable as metal salts. Furthermore, the corresponding salts can be obtained by reacting alkali metal or alkaline earth metal salts with suitable silver salts (e.g. silver nitrate).
According to the present invention, the compound represented by chemical formula 1 may be prepared and used in the form of at least one of its pharmaceutically acceptable deuterated analog, prodrug, stereoisomer, salt thereof, hydrate thereof, solvate thereof, and N-oxide thereof.
In the pharmaceutical according to the present invention, the compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be administered in a single dose or multiple dose form at the time of clinical administration. The agents of the invention may be administered using a variety of methods including, for example, rectal, pulmonary, oral, buccal, intranasal, and transdermal routes. In certain embodiments, the medicament may be administered by intraarterial injection, intravenously, intraperitoneally, enterally, parenterally, intramuscularly, subcutaneously, orally, topically, or in the form of an inhalant.
The pharmaceutical preparation of the present invention may be prepared using commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like.
Examples of the pharmaceutical of the present invention used as a preparation for oral administration include tablets, pills, hard/soft capsules, liquids, suspensions, emulsions, syrups, granules, elixirs, lozenges and the like. In addition to the active ingredient, these preparations may contain diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine) or lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol). Tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methyl cellulose, sodium carboxymethyl cellulose, and polyethylene rebuke pyrrolidine, and the like, and may optionally contain disintegrating agents (e.g., starch, agar, alginic acid or a sodium salt thereof, or boiling mixtures), absorbing agents, coloring agents, flavoring agents, sweetening agents, and the like.
One mode of administration of the agents of the invention is parenteral, e.g., by injection, and may be formulated as an aqueous or oily suspension or emulsion containing one of sesame oil, corn oil, cottonseed oil, peanut oil, and elixirs, mannitol and dextrose, or as a sterile aqueous solution and similar pharmaceutical vehicles.
When the medicament of the present invention is used by inhalation or insufflation, it may include pharmaceutically acceptable aqueous or organic solvents of solutions and suspensions, or mixtures thereof, and powders. The liquid or solid medicament may contain suitable pharmaceutically acceptable excipients as described herein. In some embodiments, the medicament is administered by the oral or nasal respiratory route for local or systemic effects. In other embodiments, the drug in a pharmaceutically acceptable solvent may be nebulized by using an inert gas. The nebulized solution may be inhaled directly from the nebulizing device or the nebulizing device may be connected to a face mask support or intermittent positive pressure ventilator. May be a solution, suspension or powder composition suitable for administration by a delivery device, preferably orally or nasally.
Furthermore, the present invention relates to a pharmaceutical kit for preventing or treating a disorder associated with LRRK2 or aberrant LRRK2 mutations, the kit comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt, deuterated analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug or deuterated analog thereof, and a label and/or instructions for using the compound for treating an indication, including a disease or condition described herein. Including a compound described herein or a pharmaceutically acceptable salt, deuterated analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof in a suitable container. The containers may be vials, jars, ampoules, preloaded syringes and intravenous bags.
Further, in another aspect of the present disclosure, the compound represented by chemical formula 1 may be administered in combination with other agents including (but not limited to): compounds that are inhibitors of apoptosis, PARP poly (ADP-ribose) polymerase inhibitors, Src inhibitors, agents for the treatment of vascular disease, hypertension, hypercholesterolemia, and type II diabetes, anti-inflammatory agents, anti-embolic agents, fibrinolytic agents, anti-platelet agents, lipid lowering agents, direct thrombin inhibitors, glycoprotein IIb/IIla receptor inhibitors, calcium channel blockers, B adrenergic receptor blockers, cyclooxygenase (e.g., COX-1 and COX-2) inhibitors, angiotensin system inhibitors (e.g., Angiotensin Converting Enzyme (ACE) inhibitors), renin inhibitors, and/or agents that bind to cell adhesion molecules and inhibit the ability of white blood cells to attach to such molecules (e.g., polypeptide antibodies, polyclonal antibodies, and monoclonal antibodies). In addition, the compounds of the present disclosure may be administered in combination with additional agents having activity in the treatment of neurodegenerative diseases. For example, in some embodiments, the compound may be administered in combination with one or more additional therapeutic agents useful in the treatment of parkinson's disease. In some embodiments, the additional therapeutic agent is L-dopa (e.g., sinemet CR), a dopamine agonist (e.g., robininol or Pramipexole), a catechol-0-methyltransferase (COMT) inhibitor (e.g., Entacapone (Entacapone)), an L-monoamine oxidase (MAO) inhibitor (e.g., selegiline or rasagiline), or an agent that increases dopamine release (e.g., Zonisamide (Zonisamide)).
Example 1
Reference is made to patent WO2006055561A3 for the preparation of (1S, 2S, 3R, 4R) -3- [ [ 5-fluoro-2- [ 3-methyl-4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] bicyclo [2.2.1] hept-5-ene-2-carboxamide, which has the following structural formula:
example 2
Reference is made to WO2016022460A1 for the preparation of N-tert-butyl-3- [ [ 5-methyl-2- [4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] benzenesulfonamide of the formula:
example 3
Reference to the Journal of Medicinal Chemistry (Journal of Medicinal Chemistry, (2019),62(22),10305-10320) for the preparation of 2- [ [1- [ 2-fluoro-4- [ [ 5-methyl-4- (1-prop-2-ylpyrazol-4-yl) pyrimidin-2-yl ] amino ] phenyl ] piperidin-4-yl ] -methylamino ] ethanol of the formula:
example 4
Reference patent WO2009143389 for the preparation of 5-chloro-4-N- (2-dimethylphosphorylphenyl) -2-N- [ 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl ] pyrimidine-2, 4-diamine, the formula of which is as follows:
example 5
Reference to Journal of Medicinal Chemistry (Journal of Medicinal Chemistry, (2012),55(8), 3852-:
example 6
Reference is made to WO02092577A1 for the preparation of N- (2-chloro-5-methoxyphenyl) -6-methoxy-7- [ (1-methylpiperidin-4-yl) methoxy ] quinazolin-4-amine of the formula:
example 7
Reference is made to WO 2013142382A 1 for the preparation of 8-bromo-2- [ (1-methylpiperidin-4-yl) amino ] -4- (4-phenoxyaniline) -6H-pyridine [4,3-d ] pyrimidin-5-one of the following formula:
example 8
Reference is made to WO2007041358A2 for the preparation of 6- (4-methylpiperazin-1-yl) -N- (5-methyl-1H-pyrazol-3-yl) -2- [ ((E) -2-phenylvinyl ] pyrimidin-4-amine, the formula of which is as follows:
example 9
Reference is made to patent WO2010128659 a1 for the preparation of 6-ethyl-3- [ 3-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] anilino ] -5- (oxan-4-ylamino) pyrazine-2-carboxamide, of the formula:
example 10
Reference is made to patent WO2007058627 a1 for the preparation of (16E) -11- (2-pyrrolidine-1-ethoxy) -14, 19-dioxine-5, 7, 27-triazatetracyclo [19.3.1.12,6.18,12] hept-1 (24), 2(27), 3,5,8(26), 9,11,16,21(25), 22-decene, of the formula:
comparative example
Reference is made to WO2011151360 for the preparation of [4- [ [ 5-chloro-4- (methylamino) pyrimidin-2-yl ] amino ] -3-methoxyphenyl ] morpholin-4-yl methanone, of the formula:
the structures of the compounds prepared in examples 1 to 10 are shown in table 1.
TABLE 1
Example 11: determination of biological Activity of Compounds
(1) Material
LRRK2G2019S enzyme, substrate (LRRK peptide), ATP, TR-FRET diluent buffer, pLRRK peptide antibody, 384-well assay plates, and DMSO.
(2) Enzyme reaction conditions: 50mM Tris pH7.5, 10mM MgCl21mM EGTA, 0.01% Brij-35, 2mM DTT, 5nM LRRK2, 134. mu.M ATP, 60 min reaction time, 23 ℃ reaction temperature, 10. mu.L total reaction volume.
Detecting the reaction conditions: 1 XDilute buffer, 10mM EDTA, 2nM antibody, reaction temperature 23 ℃ 10 u L total reaction volume.
(3) Experimental procedure
Dilution of test compounds with 100% DMSO to give stock stocks of 10mM or 100 μ M), in proportions: dilutions of buffer at 1:3.16(20 μ L +43.2 μ L) gave the highest assay concentration 100 μ M or 1 μ M. mu.L of the test solution was transferred to the assay plate and untreated blank control wells containing 5. mu.L of DMSO and 5. mu.L of a DMSO solution of a control of a known inhibitor comparative example were added sequentially to the source culture dish (384 well assay dish, Labcyte). The plates were centrifuged at 2500rpm for 1 minute and sealed with foil. A 3-fold serial dilution was performed using reaction buffer to obtain 11 test spots, and blanks of 100nL of test compound solution, known inhibitor comparative compound solution, DMSO solution after dilution were transferred to assay plates, 2 duplicate wells per concentration. The assay plates were centrifuged at 2500rpm for 1 minute and sealed with foil.
For the enzyme reaction, 5. mu.L of 50mM Tris pH7.5, 10mM MgCl2, 1mM EGTA, 0.01% Brij-35, 2mM DTT buffer containing 5nM LRRK2 enzyme was added to all wells of the assay plate. The culture dish was centrifuged to concentrate the mixture at the bottom of the well. The assay plates were incubated at 23 ℃ for 20 minutes. After incubation, 5 μ L of 1X kinase reaction buffer 2X LRRKtide succinate and ATP were added to each well and the culture dish was centrifuged to concentrate the mixture at the bottom of the well. The plates were incubated at 23 ℃ for 60 minutes.
For detection of the reaction, 10 μ L of TR-FRET dilution buffer detection reagent containing antibody reagent and 10mM EDTA was added to all wells of each well of the assay plate, and the plate was centrifuged to concentrate the mixture at the bottom of the well. Subsequently, the plates were incubated at 23 ℃ for 60 minutes. The plates were read on a Perkin elmer envision 2104 instrument in TR-FRET mode using a 340m excitation filter, a 520nm fluorescence emission filter and a 490 or 495nm terbium emission filter. The inhibitory effect of variant G2019S LRRK2 was measured in exactly the same way. All final concentrations of substrate ATP and enzyme were the same.
Data analysis was performed using Graphpad software and Kd activity was calculated.
Several compounds disclosed herein were tested according to the methods above, each concentration tested being a duplicate well, averaged, and the corresponding Kd activity values of LRRK2 and LRRK2G2019S are provided in table 2.
TABLE 2
All patents and other publications identified in this specification and examples are expressly incorporated herein by reference for all purposes. These publications are provided solely for their disclosure prior to the filing date of the present application. In this regard, no admission should be made that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. A medicament for treating or preventing a disease associated with LRRK2 kinase or abnormal LRRK2 mutant kinase activity, wherein the medicament contains an LRRK2 inhibitor, and the LRRK2 inhibitor comprises at least one of a compound represented by chemical formula 1, an optical isomer thereof, a prodrug thereof, a salt thereof, a hydrate thereof, a solvate thereof, an N-oxide thereof, and a deuterated analog thereof;
[ chemical formula 1]
In chemical formula 1, L1、L2、L3Are each independently C or N; l is4C, N, O or S;
R1independently is an unsubstituted or an amide group,
R2independently is unsubstituted, -H, -NHAr, -CH ═ CHPh,Or a 5-to 8-membered cyclic heterocyclic group containing at least one heteroatom at N, O, which is unsubstituted or substituted with a first substituent,
R3is unsubstituted, -H, halogen, C1-10Hydrocarbyl, or-NHRa;
R4independently-H, -NHAr, -CH ═ CHPh, -NHRaA substituted or unsubstituted 5-to 8-membered heterocyclylvinyl group containing N, O, S at least one heteroatom, C1-5Straight-chain or branched alkylaminosulfonyl C6-10Arylamino, di (C)1-5Straight-chain or branched alkyl) phosphoric acid group C6-10An arylamino group,A 5-to 8-membered ring heterocyclyl group containing at least one heteroatom at N, O, or a 5-to 8-membered ring heterocyclylamino group, unsubstituted or substituted with a second substituent, R5Independently is
Wherein L is5is-O-, -S-, or-NH-,
Y1is C unsubstituted or substituted by a third substituent1-10A linear or branched alkyl group;
ring Y is a benzene ring, or a 4-to 8-membered cycloheterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a fourth substituent;
R6is unsubstituted or-H;
R7is-H, C1-10Hydrocarbyl, - (CH)2)nOH、-ORc、-O(CH2)nRaHalogen, or a 4 to 8 membered ring heterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a third substituent;
R8、R9、R10、R11are all independently-H, C1-10Hydrocarbyl, - (CH)2)nOH、-O(CH2)nRa、-C(O)ORaHalogen, -CF3or-OCF3;
Each RaAre all independently-H, C1-10Hydrocarbyl radical, C1-10Cycloalkyl, aryl, or unsubstituted or substituted with a fifth substituent, 5-to 8-membered cycloheterocycloalkyl or heterocycloaryl containing at least one heteroatom of N, O;
each RbAre all independently-H, C1-10Hydrocarbyl, -O (CH)2)nRa、-NRaRcOr a 3-to 8-membered ring heterocyclic group containing at least one heteroatom at N, O, unsubstituted or substituted with a sixth substituent;
each RcAre all independently-H, C1-10Hydrocarbyl, - (CH)2)nOH, aryl, or a 4-to 8-membered ring containing at least one heteroatom of N, O unsubstituted or substituted with a third substituentHeterocycloalkyl or heterocycloaryl;
each RdAre all independently-H or-O (CH)2)nRa;
The first substituent, the second substituent, the fourth substituent, the fifth substituent and the sixth substituent are respectively and independently-OH, halogen, -CN, nitro-NH2、C1-10Hydrocarbyl, substituted or unsubstituted C3-10At least one of cycloalkyl, substituted or unsubstituted 3 to 8 membered ring heterocycloalkyl containing at least one heteroatom of N, O;
each third substituent is independently a substituted or unsubstituted 3-to 8-membered ring heterocycloalkyl containing at least one heteroatom from N, O, or a substituted or unsubstituted amino group;
each n is independently selected from any integer from 0 to 4.
2. The pharmaceutical agent of claim 1, wherein the compound of formula 1 has a structural formula as follows:
the R is3Is halogen or C1-10A hydrocarbyl group; the R is4Is C1-5Straight-chain or branched alkylaminosulfonyl C6-10Arylamino, di (C)1-5Straight-chain or branched alkyl) phosphoric acid group C6-10An arylamino group,Or a 5-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a second substituent; the R is7Is composed ofRbIs C1-10Hydrocarbyl radicals, -NRaRcOr by C1-10A 3-to 8-membered, hydrocarbyl-substituted heterocyclic group containing at least one heteroatom from N, O, RaIs C1-10Hydrocarbyl radical, RcIs- (CH)2)nOH; the R is10、R11Are all independently-H, -O (CH2)nRa、C1-10Hydrocarbyl or halogen;
3. The pharmaceutical agent of claim 1, wherein the compound of formula 1 has a structural formula as follows:
said L4N, S or O; the R is5Is composed ofOr by-O (CH)2)nRaAt least one substituted phenyl group of halogen; rbis-O (CH)2)nRa;Rais-H, or a 5 to 8 membered cyclic heterocycloalkyl or heteroaryl group containing at least one heteroatom of N, O, unsubstituted or substituted with a fifth substituent; rdis-H or-O (CH)2)nRa;
4. The pharmaceutical agent of claim 1, wherein the compound of formula 1 has a structural formula as follows:
the R is4Is a quilt C1-10A 5 to 8 membered ring heterocyclylamino substituted with a hydrocarbon group; said L4N, S or O; the R is7Is O (CH)2)nRa,RaIs aryl or a 5 to 8 membered ring heterocycloalkyl or heterocycloaryl containing at least one heteroatom of N, O, unsubstituted or substituted with a fifth substituent.
5. The pharmaceutical agent of claim 1, wherein the compound of formula 1 has a structural formula as follows:
the R is2Is a 5-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a first substituent; said L4Is N; the R is4is-CH ═ CHPh, or a substituted or unsubstituted 4 to 8 membered ring heterocyclylvinyl group containing at least one heteroatom from N, O, S; the R is5Is composed of
6. The pharmaceutical agent of claim 1, wherein the compound of formula 1 has a structural formula as follows:
the R is1Is an amide group; the R is3Is C1-10A hydrocarbyl group; the R is4Is a 5 to 8 membered ring heterocyclylamino group; the R is7Is composed ofThe R isbIs a 3-to 8-membered ring heterocyclic group containing at least one heteroatom of N, O, unsubstituted or substituted with a sixth substituent; the R is9is-O (CH)2)nRa。
8. the pharmaceutical agent according to claim 1, wherein the compound represented by chemical formula 1 is any one of the following compounds:
(1) (1S, 2S, 3R, 4R) -3- [ [ 5-fluoro-2- [ 3-methyl-4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] bicyclo [2.2.1] hept-5-ene-2-carboxamide;
(2) n-tert-butyl-3- [ [ 5-methyl-2- [4- (4-methylpiperazin-1-yl) anilino ] pyrimidin-4-yl ] amino ] benzenesulfonamide;
(3)2- [ [1- [ 2-fluoro-4- [ [ 5-methyl-4- (1-prop-2-ylpyrazol-4-yl) pyrimidin-2-yl ] amino ] phenyl ] piperidin-4-yl ] -methylamino ] ethanol;
(4) 5-chloro-4-N- (2-dimethylphosphorylphenyl) -2-N- [ 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl ] pyrimidine-2, 4-diamine;
(5)1- (4-methylphenyl) -3- [5- [7- (3-morpholin-4-ylpropoxy) quinazolin-4-yl ] sulfonyl-1, 3, 4-thiadiazol-2-yl ] urea;
(6) n- (2-chloro-5-methoxyphenyl) -6-methoxy-7- [ (1-methylpiperidin-4-yl) methoxy ] quinazolin-4-amine;
(7) 8-bromo-2- [ (1-methylpiperidin-4-yl) amino ] -4- (4-phenoxyaniline) -6H-pyridin [4,3-d ] pyrimidin-5-one;
(8)6- (4-methylpiperazin-1-yl) -N- (5-methyl-1H-pyrazol-3-yl) -2- [ ((E) -2-phenylethenyl ] pyrimidin-4-amine;
(9) 6-ethyl-3- [ 3-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] anilino ] -5- (oxa-4-ylamino) pyrazine-2-carboxamide;
(10) (16E) -11- (2-pyrrolidin-1-ethoxy) -14, 19-dioxin-5, 7, 27-triazacyclo [19.3.1.12,6.18,12] hepta-1 (24), 2(27), 3,5,8(26), 9,11,16,21(25), 22-decene.
9. The medicament of claim 1, wherein the disease comprises at least one of neurodegenerative disease, precancerous and cancerous conditions, autoimmune disease, inflammation.
10. The medicament of claim 1, wherein the disease comprises at least one of alzheimer's disease, L-dopa-induced dyskinesia, parkinson's disease, cognitive memory enhancement, central nervous system disorders, dementia, amyotrophic lateral sclerosis, kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011046968.XA CN112225703B (en) | 2020-09-28 | 2020-09-28 | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity |
PCT/CN2021/084876 WO2022062356A1 (en) | 2020-09-28 | 2021-04-01 | Medicine for treating or preventing diseases related to activity of lrrk2 kinase or abnormal lrrk2 mutant kinase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011046968.XA CN112225703B (en) | 2020-09-28 | 2020-09-28 | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112225703A true CN112225703A (en) | 2021-01-15 |
CN112225703B CN112225703B (en) | 2022-03-11 |
Family
ID=74120274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011046968.XA Active CN112225703B (en) | 2020-09-28 | 2020-09-28 | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112225703B (en) |
WO (1) | WO2022062356A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113831321A (en) * | 2021-09-18 | 2021-12-24 | 安润医药科技(苏州)有限公司 | Small molecule inhibitor of leucine-rich repeat kinase 2 and application thereof |
CN113999210A (en) * | 2021-12-03 | 2022-02-01 | 郑州大学第一附属医院 | Group of 2-phenylamino-4-triazolyl pyrimidine derivatives and application thereof |
WO2022062356A1 (en) * | 2020-09-28 | 2022-03-31 | 广州智睿医药科技有限公司 | Medicine for treating or preventing diseases related to activity of lrrk2 kinase or abnormal lrrk2 mutant kinase |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101171012A (en) * | 2004-11-15 | 2008-04-30 | 里格尔药品股份有限公司 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
CN102105150A (en) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | Phosphorous derivatives as kinase inhibitors |
CN102421761A (en) * | 2009-05-08 | 2012-04-18 | 安斯泰来制药株式会社 | Diamino heterocyclic carboxamide compound |
CN103626742A (en) * | 2005-11-01 | 2014-03-12 | 塔格根公司 | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20150202204A1 (en) * | 2012-05-24 | 2015-07-23 | Seoul National University R&Db Foundation | Method for treating tau protein-mediated degenerative neuronal disease |
WO2016022460A1 (en) * | 2014-08-03 | 2016-02-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Potent dual brd4-kinase inhibitors as cancer therapeutics |
US20170079987A1 (en) * | 2014-05-15 | 2017-03-23 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Treatment or prevention of an intestinal disease or disorder |
US20180057898A1 (en) * | 2014-12-18 | 2018-03-01 | Ruga Corporation | Antifibrotic activity of gas6 inhibitor |
WO2018058098A1 (en) * | 2016-09-26 | 2018-03-29 | Yale University | Compounds and methods for treating or preventing alzheimer's disease |
CN110678182A (en) * | 2017-02-24 | 2020-01-10 | 大邱庆北尖端医疗产业振兴财团 | Pharmaceutical composition containing a compound capable of penetrating the blood-brain barrier as an active ingredient for preventing or treating brain cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016007540A2 (en) * | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
CN112225703B (en) * | 2020-09-28 | 2022-03-11 | 广州智睿医药科技有限公司 | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity |
-
2020
- 2020-09-28 CN CN202011046968.XA patent/CN112225703B/en active Active
-
2021
- 2021-04-01 WO PCT/CN2021/084876 patent/WO2022062356A1/en active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101171012A (en) * | 2004-11-15 | 2008-04-30 | 里格尔药品股份有限公司 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
CN103626742A (en) * | 2005-11-01 | 2014-03-12 | 塔格根公司 | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
CN102105150A (en) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | Phosphorous derivatives as kinase inhibitors |
CN102421761A (en) * | 2009-05-08 | 2012-04-18 | 安斯泰来制药株式会社 | Diamino heterocyclic carboxamide compound |
US20150202204A1 (en) * | 2012-05-24 | 2015-07-23 | Seoul National University R&Db Foundation | Method for treating tau protein-mediated degenerative neuronal disease |
US20170079987A1 (en) * | 2014-05-15 | 2017-03-23 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Treatment or prevention of an intestinal disease or disorder |
WO2016022460A1 (en) * | 2014-08-03 | 2016-02-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Potent dual brd4-kinase inhibitors as cancer therapeutics |
US20180057898A1 (en) * | 2014-12-18 | 2018-03-01 | Ruga Corporation | Antifibrotic activity of gas6 inhibitor |
WO2018058098A1 (en) * | 2016-09-26 | 2018-03-29 | Yale University | Compounds and methods for treating or preventing alzheimer's disease |
US20190275040A1 (en) * | 2016-09-26 | 2019-09-12 | Yale University | Compounds and methods for treating or preventing alzheimer's disease |
CN110678182A (en) * | 2017-02-24 | 2020-01-10 | 大邱庆北尖端医疗产业振兴财团 | Pharmaceutical composition containing a compound capable of penetrating the blood-brain barrier as an active ingredient for preventing or treating brain cancer |
Non-Patent Citations (4)
Title |
---|
JINWEI ZHANG等: "Characterization of TAE684 as a potent LRRK2 kinase inhibitor", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
RAASAY S. JONES等: "Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice", 《NEUROBIOLOGY OF AGING》 * |
TAO YANG等: "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
王林等: "帕金森病研究中LRRK2激酶抑制剂的进展", 《中南药学》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022062356A1 (en) * | 2020-09-28 | 2022-03-31 | 广州智睿医药科技有限公司 | Medicine for treating or preventing diseases related to activity of lrrk2 kinase or abnormal lrrk2 mutant kinase |
CN113831321A (en) * | 2021-09-18 | 2021-12-24 | 安润医药科技(苏州)有限公司 | Small molecule inhibitor of leucine-rich repeat kinase 2 and application thereof |
CN113831321B (en) * | 2021-09-18 | 2023-01-31 | 安润医药科技(苏州)有限公司 | Small molecule inhibitor of leucine-rich repeat kinase 2 and application thereof |
CN113999210A (en) * | 2021-12-03 | 2022-02-01 | 郑州大学第一附属医院 | Group of 2-phenylamino-4-triazolyl pyrimidine derivatives and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112225703B (en) | 2022-03-11 |
WO2022062356A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112225703B (en) | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | |
DK2428508T3 (en) | Diamino heterocyclic carboxamide COMPOUND | |
CN112043710A (en) | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | |
US8314234B2 (en) | Bicyclic pyrimidine kinase inhibitors | |
JP6945015B2 (en) | N2, N4-diphenylpyrimidine-2,4-diamine derivative, a method for producing the same, and a pharmaceutical composition containing the N2, N4-diphenylpyrimidine-2,4-diamine derivative as an active ingredient for the prevention or treatment of cancer. | |
JP6235078B2 (en) | Substituted pyridazine carboxamide compounds | |
KR101656382B1 (en) | pyrimidine-2,4-diamine derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient | |
TWI736531B (en) | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
JPWO2004020434A1 (en) | Nitrogen-containing aromatic ring derivatives | |
BR112013018212A2 (en) | DIETARY HYDRAZIDE ACETYLENE CONTAINING TYROSINE KINASE INHIBITORS | |
TW201623260A (en) | Novel disubstituted 1,2,4-triazine compounds | |
WO2023083194A1 (en) | Wee1 protein kinase degradation agent and use thereof | |
TWI786303B (en) | Crystal forms and applications of active compounds inhibiting CDK4/6 | |
KR20170095239A (en) | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kβ INHIBITORS | |
KR102550999B1 (en) | 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivatives, preparation method thereof, pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
RU2526253C9 (en) | Diaminoheterocyclic carboxamide compound | |
CN114957216A (en) | Target inhibitor, preparation method, application and pharmaceutical composition thereof | |
BR112017020945B1 (en) | SESQUI-MALEATE CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR, METHOD AND PROCESS OF PREPARATION AND USES THEREOF | |
CN104693204A (en) | Pyrrolo[2,1-f][1,2,4]triazine derivatives, preparing methods thereof and uses of the derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |